<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        31-590-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EZEACT PLUS 40MG/12.5MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZILSARTAN MEDOXOMIL,CHLORTHALIDONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        71.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Takeda Pharmaceutical Company Limited, Osaka Plant " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Takeda Pharmaceutical Company Limited, Osaka Plant 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 651]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACEUTICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BATTERJEE PHARMACETICAL FACTORY
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ezeact PLUS contains two active substances, azilsartan medoxomil and chlortalidone, that are used for<br />treating high blood pressure (hypertension) in adult patients (over 18 years of age):<br />- Azilsartan medoxomil belongs to a class of medicines called angiotensin II receptor blockers. It lowers<br />the blood pressure by relaxing the blood vessels.<br />- Chlortalidone belongs to a class of medicines called diuretics. It lowers the blood pressure by helping the<br />body to get rid of extra fluid by making your kidneys produce more urine.<br />You will only be given Ezeact PLUS if treatment with azilsartan medoxomil alone has not adequately<br />controlled your blood pressure. When given together, the two active substances in Ezeact PLUS help to<br />lower the blood pressure more than if either of them were given alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ezeact PLUS if you:<br />- are allergic (hypersensitive) to azilsartan medoxomil or to chlortalidone, or any of the other<br />ingredients of this medicine (listed in section 6).<br />- are pregnant. (Ezeact PLUS should not be used in pregnancy - see pregnancy section).<br />- have severe liver disease.<br />- have severe kidney disease.<br />- do not produce any urine.<br />- have low blood sodium levels that cannot be corrected despite treatment.<br />- have abnormally high levels of calcium in your blood.<br />- have abnormally high levels of uric acid in your blood that cause symptoms (gout).</p><p>- have diabetes or impaired kidney function and you are treated with a blood pressure lowering<br />medicine containing aliskiren.<br />Warnings and precautions<br />Before you take, or whilst you are taking Ezeact PLUS, tell your doctor if you:<br />- have kidney problems<br />- are on dialysis or had a recent kidney transplant<br />- suffer from liver problems<br />- have heart problems (including heart failure, recent heart attack)<br />- have ever had a stroke<br />- have low blood pressure or feel dizzy, weak, restless or lightheaded<br />- have muscle pains or cramps, or muscular fatigue<br />- have nausea and vomiting, diarrhoea, dry mouth, thirst, or tiredness<br />- are taking diuretics (a water tablet), or<br />- develop a decreased amount of urine<br />These may be signs of severe dehydration or salt-depletion. Your doctor should correct these problems<br />before you take Ezeact PLUS<br />- have a disease of the adrenal gland called primary hyperaldosteronism<br />- have been told that you have a narrowing of the valves in your heart (called &ldquo;aortic or mitral valve<br />stenosis&rdquo;) or that the thickness of your heart muscle is abnormally increased (called &ldquo;hypertrophic<br />obstructive cardiomyopathy&rdquo;)<br />- are being treated with lithium (used for treating mental health problems).<br />- are taking any of the following medicines used to treat high blood pressure:<br /> an &ldquo;ACE-inhibitor&rdquo; (for example enalapril, lisinopril, ramipril, etc.), in particular if you have<br />diabetes-related kidney problems.<br /> Aliskiren<br />Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium,<br />calcium, sodium, magnesium or chloride) in your blood at regular intervals. Your doctor may also check<br />your glucose, uric acid, cholesterol and triglyceride (blood lipid) levels.</p><p>See also information under the heading &ldquo;Do not take Ezeact PLUS&rdquo;.<br />You must tell your doctor if you think you are (or might become) pregnant. Ezeact PLUS should not be used<br />during pregnancy, and must be stopped if you become pregnant, as it may cause serious harm to your baby if<br />used (see pregnancy section).<br />Children and adolescents<br />There is no experience with the use of Ezeact PLUS in children or adolescents under 18 years of age.<br />Therefore,<br />Ezeact PLUS should not be given to children or adolescents under 18 years of age.<br />Other medicines and Ezeact PLUS<br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including<br />medicines obtained without a prescription.<br />Ezeact PLUS can affect the way some other medicines work and some medicines can have an effect on<br />Ezeact PLUS. In particular, tell your doctor if you are taking any of the following medicines:<br />- Lithium (a medicine for mental health problems)<br />- Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, diclofenac or celecoxib<br />(medicines to relieve pain and inflammation)<br />- Aspirin (acetylsalicyclic acid) if taking more than 3 g per day (medicine to relieve pain and<br />inflammation)<br />- Medicines that increase the amount of potassium in your blood; these include potassium supplements,<br />potassium-sparing medicines (certain &lsquo;water tablets&rsquo;) or salt substitutes containing potassium<br />- Medicines associated with low blood potassium (hypokalaemia) such as corticosteroids (e.g.<br />prednisone), ACTH (a hormone), amphotericin (an antifungal medicine) and carbenoxolone (used to&nbsp;treat mouth ulcers)<br />- Heparin (a medicine for thinning the blood)<br />- Aliskiren or other medicines to lower your blood pressure, such as enalapril, lisinopril, ramipril or<br />valsartan, telmisartan, irbesartan<br />- Other medicines used to treat high blood pressure, diabetes, gout, or asthma<br />- Digitalis (a medicine for heart problems)<br />- Anticholinergics such as atropine used for abdominal or stomach spasms or cramps<br />- Amantadine (a medicine for Parkinson&acute;s disease)<br />- Colestyramine (used to reduce cholesterol levels in the blood)<br />- Ciclosporin (used to treat rheumatic disease or after a transplant)<br />- Medicines to treat cancer such as cyclophosphamide or methotrexate<br />- Vitamin D and calcium supplements<br />Your doctor may need to change your dose and/or to take other precautions if you are taking an<br />ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Ezeact PLUS&rdquo; and<br />&ldquo;Warnings and precautions&rdquo;).<br />Pregnancy and breast-feeding<br />Pregnancy<br />You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise<br />you to stop taking Ezeact PLUS before you become pregnant or as soon as you know you are pregnant and<br />will<br />advise you to take another medicine instead of Ezeact PLUS.<br />Ezeact PLUS should not be used in pregnancy, and must be stopped if you become months pregnant, as it<br />may cause serious harm to your baby if used.<br />Breast-feeding<br />Tell your doctor if you are breast-feeding or about to start breast-feeding. Ezeact PLUS is not recommended<br />for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to<br />breastfeed,<br />especially if your baby is newborn, or was born prematurely.<br />Driving and using machines<br />Ezeact PLUS is unlikely to have an effect on driving or using machines. However some people may feel tired<br />or<br />dizzy when taking Ezeact PLUS and if this happens to you, do not drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Ezeact PLUS exactly as your doctor has told you. You should check with your doctor or<br />pharmacist if you are not sure. It is important to keep taking Ezeact PLUS every day.<br />Ezeact PLUS is for oral use. Take the tablet with plenty of<br />water. You can take Ezeact PLUS with or without food.<br />- The usual starting dose is one 40 mg/12.5 mg tablet once a day. Your doctor may increase this dose to<br />a maximum of one 40 mg/25 mg tablet once a day depending on blood pressure response.<br />- If you have recently lost body fluids e.g. through vomiting or diarrhoea, or by taking water tablets, you<br />should tell your doctor before you start taking Ezeact PLUS.<br />- If you suffer from other coexisting illnesses such as heart failure your doctor will decide on the most<br />appropriate starting dose.<br />A reduction in your blood pressure will be measureable within 1-2 weeks of starting treatment and the full<br />effect of your dose will be observed by 4 weeks.<br />If you take more Ezeact PLUS than you should<br />If you take too many tablets, or if someone else takes your medicine, contact your doctor immediately. You<br />may feel faint or dizzy if you have taken more than you should.</p><p>If you forget to take Ezeact PLUS<br />Do not take a double dose to make up for a forgotten dose. Just take the next dose at the usual time.<br />If you stop taking Ezeact PLUS<br />If you stop taking Ezeact PLUS, your blood pressure may increase again. Therefore do not stop taking<br />Ezeact PLUS without first talking to your doctor about alternative treatment options.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Ezeact PLUS can cause side effects, although not everybody gets them.<br />Ezeact PLUS<br />STOP taking Ezeact PLUS and seek medical help immediately if you have any of the following<br />serious allergic reactions, which occur rarely (less than 1 in 1000 people):<br />- Difficulties in breathing, or swallowing, or swelling of the face, lips, tongue and/or throat<br />(angioedema)<br />Other possible side effects include:<br />Very common side effects affecting more than 1 in 10 people:<br />- Increased serum creatinine in the blood (an indicator of kidney function)<br />Common side effects affecting less than 1 in 10 people:<br />- Dizziness and feeling faint when getting up<br />- Diarrhoea<br />- Nausea<br />- Low blood pressure (hypotension), which may make you feel faint or dizzy<br />- Feeling tired (fatigue)<br />- Muscle spasms<br />- Increased uric acid in the blood<br />Uncommon side effects affecting less than 1 in 100 people:<br />- Skin rash and itching<br />- Fainting (syncope)<br />- Sensation of tingling, pins and needles (paraesthesia)<br />- Vomiting<br />- Gout which causes pain and swelling in the joints<br />- Deficiency in red blood cells (anaemia)<br />- Increase or decrease in blood potassium<br />- Decrease in blood sodium levels<br />- Increased blood glucose levels<br />Adverse reactions reported with one of the individual components may be potential adverse reactions<br />with Ezeact PLUS, even if not observed in clinical studies with this product.</p><p>Azilsartan medoxomil<br />In patients taking azilsartan medoxomil alone, the following additional side effects have been reported:<br />Common side effects affecting less than 1 in 10 people:<br />- Swelling of the hands, ankles or feet is more common when azilsartan medoxomil is taken with<br />amlodipine (a calcium channel blocker for treating hypertension) than when azilsartan<br />medoxomil is taken alone (less than 1 in 100 users)<br />Uncommon side effects affecting less than 1 in 100 people:<br />- Migraine<br />Rare side effects affecting less than 1 in 1000 people:<br />- Changes in blood test results including decreased levels of a protein in the red blood cells<br />(haemoglobin)<br />Chlortalidone<br />In patients taking chlortalidone alone the following additional side effects have been reported:<br />Very common side effects affecting more than 1 in 10 people:<br />- Increased levels of fat (blood lipids) in the blood<br />Common side effects affecting less than 1 in 10 people:<br />- Loss of appetite<br />- Upset stomach<br />- Itchy skin rash</p><p>- Low blood levels of magnesium<br />Rare side effects affecting less than 1 in 1000 people:<br />- Sugar in the urine (glycosuria)<br />- Worsening of diabetes<br />- Irregular heart beat<br />- Yellowing of the skin or eyes caused by liver problems (jaundice)<br />- Increased sensitivity to sunlight<br />- Inflamed blood vessels in the skin<br />- Breathing problems due to water (oedema) in the lungs<br />- Inflammation of the kidneys<br />- Headache<br />- Stomach pain<br />- Constipation<br />- Increased calcium in the blood<br />- Changes in the number of cells in the blood, including increase in certain white blood cells<br />(eosinophilia), low white blood cell count (leucopenia, agranulocytosis) and low platelet count<br />(thrombocytopenia)<br />Very rare side effects affecting less than 1 in 10,000 people:<br />- Low blood levels of chloride in the blood<br />- Inflammation of the pancreas which causes severe stomach and back pain<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed<br />in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug<br />Safety Centre (NPC).<br />By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not use Ezeact PLUS after the expiry date which is stated on the carton and blister after EXP. The expiry<br />date refers to the last day of the month.<br />Store Ezeact PLUS in the original package in order to protect it from moisture. Do not store above 30<br />&deg;C.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Ezeact PLUS contains<br />- The active substances are azilsartan medoxomil (as potassium) and chlortalidone either<br />40 mg/12.5 mg or 40 mg/25 mg.<br />- The other ingredients are mannitol, fumaric acid (for pH adjustment), sodium hydroxide (for pH<br />adjustment), hydroxypropylcellulose, crospovidone (Type A), microcrystalline cellulose, magnesium<br />stearate, titanium dioxide (E171), iron oxide, red and iron oxide, black (E172), hypromellose 2910,<br />talc, macrogol 8000 and shellac.<br />.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Ezeact PLUS looks like and contents of the pack
Ezeact PLUS 40 mg/12.5 mg are pale red, round, biconvex, film-coated tablets with “A/C 40/12.5” on one side.
Ezeact PLUS 40 mg/25 mg are light red, round, biconvex, film-coated tablets with “A/C 40/25” on one side.
Ezeact PLUS is provided in desiccated or non-desiccated aluminum/aluminum blister packs, with each
blister strip having 14 tablets. The strips of 14 tablets are placed within cartons containing:
- 14, 28 or 56 tablets for 40 mg/12.5 mg tablets
- 14, 28 or 56 tablets for 40 mg/25 mg tablets
Not all pack sizes may be marketed
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder<br />Batterjee Pharmaceutical Factory<br />Industrial Area-Phase-IV,<br />Jeddah-21443, Kingdom of Saudi Arabia<br />Manufactured by:<br />Takeda Pharmaceutical Company Limited<br />17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan<br />Primary packaging site:<br />AndersonBrecon Inc.<br />4545 Assembly Drive<br />Rockford IL 61109, USA</p><p>Secondary packaging site:<br />Batterjee Pharmaceutical Factory<br />Industrial Area-Phase-IV,<br />Jeddah-21443, Kingdom of Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>إيزكت بلس عقار لا يعطى إلا بوصفة طبية وهو يحتوي على مادة الأزيلسارتان ميدوكسوميل المانعة لمستقبلات الأنجيوتنسين ومادة<br />الكلورثاليدون المدرة للبول.<br />ويستخدم عقار إيزكت بلس لعلاج ارتفاع ضغط الدم: <br /> . في الحالات التي لا يكفي فيها دواء واحد لخفضارتفاع ضغط الدم لديك <br /> . أو كدواء أول لخفض ارتفاع ضغط الدم لديك إذا رجح طبيبك أنك ستحتاج إلى أكثر من دواء واحد</p><p>ليس من المعروف ما إذا كان عقار إيزكت بلس دواءا آمنا وفعالا للأطفال دون الثامنة عشرة من العمر.</p><p>من هو الشخص الذي لا ينبغي أن يتعاطى إيزكت بلس؟<br />لا تتعاطى عقار إيزكت بلس إذا:<br /> . كان التبول لديك قليلا بسبب مشاكل في الكلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ما الذي ينبغي علي أن أخبره للطبيب قبل البدء بتعاطي إيزكت بلس؟<br />قبل البدء بتعاطي إيزكت بلس، أخبر الطبيب:<br /> . إن كنت قد أخبرت سابقا بأن لديك مستويات غير طبيعية من الملح (الشوارد) في دمك <br /> . كان لديك مشاكل في الكلى <br />  تعرضت لمشاكل قلبية أو سكتة دماغية <br />  كنت تعاني من التقيؤ أو الإسهال <br /> &quot; ؟ كنت حاملا أو تنوين الحمل .راجعي فقرة&quot; ما هي أهم معلومات ينبغي علي معرفتها عن عقار إيزكت بلس <br />كنت ترضعين أو تنوين الإرضاع، فليس من المعلوم ما إذا كان عقار إيزكت بلس ينتقل إلى حليب الأم أم لا .لذلك ينبغي أن تقرري <br />وطبيبك ما إذا كنت ستأخذين عقار إيزكت بلس أو سترضعين طفلك .إذ لا ينبغي أن تجمعي بين الاثنين .واسألي طبيبك عن  أنت<br /> . أفضل السبل لتغذية طفلك إذا كنت ستأخذين إيزكت بلس</p><p>أخبر الطبيب عن كل الأدوية التي تتعاطاها، بما فيها الأدوية المأخوذة بوصفة طبية والمأخوذة بدون وصفة طبية والفيتامينات و المكملات العشبية.<br />وأخبر طبيبك على وجه الخصوص إذا كنت تتعاطى:<br /> . أدوية لمعالجة ارتفاع ضغط الدم أو المشاكل القلبية <br />  الحبوب المدرة للبول <br />  كربونات الليثيوم (ليثوبيد) أو سيترات الليثيوم <br /> .( ديجوكسين (لانوكسين</p><p>حاصرات نظام الرینین-أنجیوتنسین حیث أن تناول إیزكت بلس مع حاصرات نظام الرینین-أنجیوتنسین مرتبط بتفاعلات دوائیة <br /> ضارة تتسبب بمشاكل الكلى وارتفاع نسب البوتاسیوم فى الدم<br />واسأل الطبيب إن كنت غير متأكد من وجود أحد الأدوية المذكورة أعلاه بين الأدوية التي تتناولها.<br />وكن على معرفة بالأدوية التي تتعاطاها .حضر قائمة بها وأرها للطبيب أو الصيدلاني عندما يوصف لك دواء جديد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p> . تناول دواء إيزكت بلس كما يخبرك طبيبك تماما <br /> . سيخبرك الطبيب كم تأخذ من الدواء ومتى <br /> . قد يصف لك الطبيب أدوية أخرى تأخذها إلى جانب عقار إيزكت بلس لمعالجة ارتفاع ضغط الدم <br /> . يمكن أن تتناول دواء إيزكت بلس مع الطعام أو بدونه <br /> . إذا فاتتك إحدى الجرعات، فخذها في وقت لاحق من اليوم نفسه ولا تأخذ أكثر من جرعة واحدة من إيزكت بلس في اليوم <br />إذا تناولت كمية زائدة من إيزكت بلس وظهرت لديك أعراضانخفاضضغط الدم والدوخة، فاتصل بطبيبك للاستشارة .راجع فقرة </p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">يمكن&nbsp;أن يسبب إيزكت بلس أعراضا جانبية خطيرة، ومنها:<br /> &quot; ؟ راجع فقرة&quot; ما هي أهم المعلومات التي ينبغي علي معرفتها عن دواء إيزكت بلس <br /> : يرجح أن يحصل لديك انخفاضفي ضغط الدم وشعور بالدوخة إذا كنت أيضا <br /> تتعاطى حبوبا مدرة للبول <br /> تتبع نظام حمية غذائية قليل الملح <br /> تتناول أدوية أخرى تؤثر على ضغط الدم <br /> تتعرق بكثرة <br /> تعاني من التقيؤ أو الإسهال <br /> لا تشرب كميات كافية من السوائل <br />إذا شعرت بالدوار أوالدوخة، استلق واتصل بطبيبك فورا .وإذا أغمي عليك، أوصي شخص ليتصل بالطبيب أو يطلب المساعدة الطبية.<br />وتوقف عن تعاطي إيزكت بلس.<br />تغيرات  المشاكل الكلوية :يمكن أن تتفاقم المشاكل الكلوية لدى الأشخاصالمصابين أساسا بمرض كلوي .وبعضالأشخاص قد تظهر لديهم <br />بإيزكت  في الاختبارات الدموية الخاصة بوظائف الكليتين وقد يحتاجون لتقليل جرعة الإيزكت بلس أو قد يتوجب عليهم إيقاف العلاج<br /> بلس&nbsp;.أثناء العلاج بعقار إيزكت سى إل دى، يمكن لبعضالأشخاصالذين يعانون من نوبات قلبية حادة أو ضيق الشريان المغذي<br />للوفاة  للكلية أو من فقدان كميات كبيرة من سوائل الجسم بسبب الغثيان أو التقيؤ أو النزيف أو الصدمة، فقد يتعرضوا لفشل كلوي مفاجئ أو<br /> . في حالات نادر</p><p> . في حالات نادرة</p><p>إخراج كميات كبيرة أو قليلة من البول.  التشوش  جفاف الحلق </p><p>نبضات قلب سريعة أو غير سوية.  نوبات مرضية  العطش </p><p>تعب عضلى (شعور بالإرهاق).  . آلام عضلية أو تشنجات  ( إفتقاد النشاط (الكسل </p><p>غثيان وتقيؤ  ضجر  الوهن </p><p>امساك  النعاس </p><p>مشاكل السوائل وأملاح الجسم (الشوارد) .أخبر طبيبك إذا ظهرت لديك أي من الأعراضالتالية <br />ارتفاع مستويات حمضالبول في الدم .يمكن أن يتعرضالأشخاصالذين يعانون من ارتفاع مستويات حمضالبول في الدم للإصابة <br /> . بالنقرس .وإذا كنت مصابا أساسا بالنقرس، فأخبر طبيبك إذا ما تفاقمت أعراضالنقرس لديك<br />أكثر الآثار الجانبية للإيزكت بلس شيوعا هي : <br />- الدوخة<br />- والوهن<br />وليست الآثار المذكورة هي كل الآثار الجانبية المحتملة لتعاطي إيزكت بلس لذلك أخبر طبيبك عن أي أثر جانبي يزعجك أو لا يزول.<br />اتصل بطبيبك للاستشارة الطبية بشأن الآثار الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p> . يحفظ إيزكت بلس في درجة حرارة أقل من 30 درجة مئوية <br /> . يحفظ إيزكت بلس في العبوة الأصلية التي حصلت عليها من الصيدلاني أو الطبيب .لا تضع إيزكت بلس في عبوة مختلفة <br /> . حافظ على إغلاق العبوة بإحكام، واحفظ عقار إيزكت بلس بعيدا عن الضوء</p><p>احفظ عقار إيزكت بلس وجميع الأدوية بعيدا عن متناول الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">المكونات الفعالة :مادة الأزيلسارتان ميدوكسوميل ومادة الكلورثاليدون<br />المكونات غير الفعالة :المانيتول، والسليلوز دقيق البلورات، وحمضالفيوماريك، وهيدروكسيد الصوديوم، والهيدروكسيبروبيل سليلوز،<br />والكروسبوفيدون، وستيرات المغنيسيوم، والهيبروميلوز 2910 ، والتلك، وثاني أكسيد التيتانيوم، وأكسيد الحديديك الأحمر، والبولي إيثلين<br />. وحبر الطباعة الرمادي 1 ،.F جليكول 800</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>ايزيكيت بلس 40 ملجم/12.5 أحمر باهت ، مستدير ، محدب من الجانبين ، أقراص مغلفة و&nbsp;&ldquo;A/C 40/12.5&rdquo; في جانب واحد\</p><p>ايزيكيت بلس 40 ملجم/25&nbsp;أحمر باهت ، مستدير ، محدب من الجانبين ، أقراص مغلفة و&nbsp;&ldquo;A/C 40/25&rdquo; في جانب واحد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>صاحب رخصة التسويق :<br />بترجي فارما<br />المنطقة الصناعية المرحلة الرابعة،<br />جده - 21443 المملكة العربية السعودية.<br />المصنع:<br />Takeda Pharmaceutical Company Limited<br />17-85, Jusohonmachi, 2-chome<br />Osaka 532-8686, Japan<br />موقع التغليف الأولى:<br />AndersonBrecon Inc.<br />4545 Assembly Drive<br />Rockford IL 61109, USA<br />موقع التغليف الثانوى والإفراج النهائى:<br />بترجي فارما<br />المنطقة الصناعية المرحلة الرابعة،<br />جده - 21443 المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ezeact PLUS 40 mg/12.5 mg film-coated tablets.
Ezeact PLUS 40 mg/25 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ezeact PLUS 40 mg/12.5 mg film-coated tablets:
Each tablet contains 40 mg of azilsartan medoxomil (as potassium) and 12.5 mg chlortalidone.
Ezeact PLUS 40 mg/25 mg film-coated tablets:
Each tablet contains 40 mg of azilsartan medoxomil (as potassium) and 25 mg chlortalidone.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Ezeact PLUS 40 mg/12.5 mg film-coated tablets:
Pale red, round (approximately 9.7 mm in diameter), biconvex, film-coated tablet with A/C 40/12.5 on one
side.
Ezeact PLUS 40 mg/25 mg film-coated tablets:
Light red, round (approximately 9.7 mm in diameter), biconvex, film coated tablet with A/C 40/25 on one
side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of hypertension in adults.<br />Ezeact PLUS is a fixed-dose combination indicated in adults whose blood pressure is not adequately<br />controlled by azilsartan medoxomil monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Adults<br />The recommended starting dose is 40 mg/12.5 mg once daily in patients whose blood pressure is not<br />adequately controlled with current antihypertensive monotherapy such as Ezeact 40 mg or Ezeact 80 mg.<br />If needed the dose may be increased to a maximum of 40 mg/25 mg once daily.<br />Near-maximal antihypertensive effect is usually evident within 1-2 weeks of dosing, with maximal effects<br />attained by 4 weeks.<br />Special populations<br />Older people (65 years and over)<br />No initial dose adjustment with Ezeact PLUS is necessary in elderly patients; caution should be exercised and<br />close medical monitoring is recommended in the very elderly (&ge; 75 years), who may be at increased risk of<br />adverse events (see section 5.2).<br />Renal impairment<br />Chlortalidone, a component drug of Ezeact PLUS, should not be used in patients with severe renal<br />impairment (GFR &lt;30 mL/min/1.73m2) and anuria (see section 4.3). There is no experience regarding the<br />administration of Ezeact PLUS in patients with recent kidney transplantation. No dose adjustment is<br />required in patients with mild or moderate renal impairment (GFR &ge;30-&lt;90 mL/min/1.73m2).<br />Hepatic impairment<br />Chlortalidone, a component drug of Ezeact PLUS, should not be used in patients with severe hepatic&nbsp;impairment (see section 4.3). There is limited experience of use of Ezeact PLUS in patients with mild to<br />moderate hepatic impairment; however, no initial dose adjustment of Ezeact PLUS is necessary in patients<br />with mild to moderate hepatic impairment.<br />Thiazides should be used with caution in patients with impaired hepatic function (see sections 4.3 and 4.4).<br />Minor changes in the fluid and electrolyte balance due to thiazide diuretics may precipitate hepatic coma.<br />Close monitoring is recommended (see section 5.2).<br />Intravascular volume depletion<br />For patients with depletion of intravascular volume or salt (e.g. patients with vomiting, diarrhoea or taking<br />high doses of diuretics), Ezeact PLUS should be initiated under close medical supervision only after<br />correct volume has been obtained (see section 4.4).<br />A transient hypotensive response due to volume depletion does not preclude patients from further treatment,<br />which usually can be continued without difficulty once the blood pressure and volume status have stabilized.<br />Heart failure<br />Caution should be exercised in hypertensive patients with congestive heart failure as there is no experience<br />of use of Ezeact PLUS in these patients (see section 4.4).<br />Black population<br />No dose adjustment is required in the black population, who are commonly characterised as &ldquo;low renin&rdquo;<br />hypertensives with an attenuated response to Renin-Angiotensin-Aldosterone System (RAAS) blockers. The<br />blood pressure effect and safety profile of Ezeact PLUS in black patients are similar to those in the non-black<br />population.<br />Paediatric population<br />The safety and efficacy of Ezeact PLUS in children and adolescents aged 0 to &lt;18 years have not<br />been established. No data are available.<br />Method of administration<br />Ezeact PLUS is for oral use and may be taken with or without food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance or to any of the excipients.
- Pregnancy (see sections 4.4 and 4.6).
- Severe hepatic impairment.
- Severe renal impairment (GFR <30 mL/min/1.73m2).
- Anuria.
- Refractory hyponatraemia (see sections 4.4 and 4.8).
- Hypercalcaemia (see sections 4.4).
- Symptomatic hyperuricaemia (see sections 4.4 and 4.8).
- Concomitant use of Ezeact PLUS with aliskiren-containing products is contraindicated in patients with
diabetes mellitus or renal impairment (GFR <60 mL/min/1.73m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dual blockade of the Renin-Angiotensin-Aldosterone System (RAAS)<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren<br />increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure).<br />Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren is therefore not recommended (see sections 4.5 and 5.1).<br />If dual blockade therapy is considered absolutely necessary, this should only occur under specialist<br />supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.<br />ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with<br />diabetic nephropathy.<br />Activated renin-angiotensin-aldosterone system<br />In patients whose vascular tone and renal function depend predominantly on the activity of the reninangiotensin-<br />aldosterone system (e.g. patients with congestive heart failure, or underlying renal disease,<br />including bilateral renal artery stenosis ), treatment with medicinal products that affect this system, such as<br />ACE-inhibitors and angiotensin II receptor blockers, has been associated with acute hypotension, azotaemia,<br />oliguria or, rarely, acute renal failure. The possibility of similar effects cannot be excluded with Ezeact<br />PLUS.<br />Evaluation of hypertensive patients with activated RAAS should include periodic assessment of renal<br />function and electrolyte levels.<br />Excessive blood pressure decreases in patients with ischaemic cardiomyopathy or ischaemic cerebrovascular<br />disease could result in a myocardial infarction or stroke.<br />Renal impairment<br />Chlortalidone, a component drug of Ezeact PLUS, should not be used in severe renal impairment (GFR<br />&lt;30 mL/min/1.73m2) (see section 4.3). No dose adjustment is required in patients with mild or moderate<br />renal impairment.<br />Observe for worsening renal function in patients with renal impairment by periodic monitoring of serum<br />creatinine and electrolyte levels. Patients with renal impairment are more likely to report abnormally high<br />serum creatinine values. In these patients, Ezeact PLUS should be carefully titrated with monitoring of<br />blood pressure and renal function parameters. Renal function may worsen in patients with renal artery<br />stenosis.</p><p>Chlortalidone should be used with caution in patients with renal impairment, since chlortalidone may<br />precipitate azotaemia. If progressive renal impairment becomes evident consider withholding or<br />discontinuing diuretic therapy.<br />Kidney transplantation<br />There is currently no experience on the use of Ezeact PLUS in patients who have recently undergone kidney<br />transplantation.<br />Hepatic impairment<br />Chlortalidone, a component drug of Ezeact PLUS, should not be used in severe hepatic impairment (see<br />section<br />4.3).<br />There is limited experience of use of Ezeact PLUS in patients with mild to moderate hepatic impairment,<br />however, based on PK data, no initial dose adjustment of Ezeact PLUS is necessary in patients with mild<br />to moderate hepatic impairment. Minor changes in the fluid and electrolyte balance due to thiazide<br />diuretics may precipitate hepatic coma. Close monitoring is therefore recommended (see section 5.2).</p><p>For patients with possible depletion of intravascular volume or salt depletion (e.g. patients with vomiting,<br />diarrhoea, or patients taking high doses of diuretics), Ezeact PLUS should be initiated under close medical<br />supervision (see section 4.2). Volume- and/or salt- depletion should be corrected before initiating Ezeact<br />PLUS treatment.<br />Primary hyperaldosteronism<br />Patients with primary hyperaldosteronism generally will not respond to antihypertensive medicinal products<br />acting through inhibition of the renin-angiotensin system. Therefore, the use of Ezeact PLUS is not<br />recommended in these patients.<br />Electrolyte imbalance<br />As for any patient receiving diuretic therapy, determination of serum electrolytes should be performed<br />periodically.<br />Thiazides can cause fluid or electrolyte imbalance (including hypokalaemia, hypercalcaemia, hyponatraemia,<br />and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst,<br />asthenia, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria,<br />tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8). Fluid and<br />electrolyte imbalance should be corrected prior to initiating treatment with Ezeact PLUS.<br />Hypokalaemia<br />Hypokalaemia is a dose-dependent adverse reaction that may develop with chlortalidone monotherapy.<br />Concurrent therapy with azilsartan medoxomil has been shown to reduce chlortalidone-associated<br />hypokalaemia. Coadministration of digitalis may exacerbate the adverse effects of hypokalaemia.<br />Hypokalaemia should be corrected prior to initiating treatment with Ezeact PLUS.<br />Hyperkalaemia<br />Due to the antagonism of the angiotensin II receptors by the azilsartan medoxomil component of Ezeact<br />PLUS, hyperkalaemia may occur. Although clinically significant hyperkalaemia has not been documented<br />with Ezeact PLUS, risk factors for developing hyperkalaemia include renal impairment and/or heart<br />failure, and diabetes mellitus. Potassium-sparing diuretics, potassium supplements or potassium-containing<br />salt substitutes should be co-administered cautiously with Ezeact PLUS (see section 4.5).<br />Hyponatraemia and hypochloraemic alkalosis</p><p>Thiazides have been shown to induce hyponatraemia. Ezeact PLUS should not be used in patients with<br />refractory hyponatraemia (see section 4.3). Chloride deficit is generally mild and usually does not require<br />treatment.<br />Hypercalcaemia<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum<br />calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be evidence<br />of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid<br />function. Ezeact PLUS should not be used in patients with hypercalcaemia (see section 4.3).<br />Hypomagnesaemia<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in<br />hypomagnesaemia (see section 4.5).<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy<br />As with other agents causing vasodilation or volume depletion special caution is indicated in patients<br />suffering from aortic or mitral valve stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).<br />Metabolic and endocrine effects<br />Thiazide therapy may impair glucose tolerance, so a dose adjustment of insulin or antidiabetic therapy may<br />be required. Latent diabetes mellitus may become manifest during thiazide therapy. An increase in<br />cholesterol and triglyceride levels has been associated with thiazide diuretic therapy.</p><p>Hyperuricaemia<br />Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving chlortalidone or<br />other thiazide diuretics. Ezeact PLUS should not be used in patients with symptomatic hyperuricaemia (see<br />section 4.3).<br />Pregnancy<br />Ezeact PLUS should not be used in pregnancy (see section 4.3).<br />Angiotensin II receptor blockers should not be initiated during pregnancy. Unless continued angiotensin II<br />receptor blocker therapy is essential, patients planning pregnancy should be changed to alternative<br />antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy<br />is diagnosed, treatment with angiotensin II receptor blockers should be stopped immediately, and, if<br />appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />Diuretics should not be used for the management of oedema or hypertension in pregnancy (see section 4.6).<br />Lithium<br />As with other angiotensin II receptor blockers, the combination of lithium and Ezeact PLUS is not<br />recommended<br />(see section 4.5).<br />Paediatric population<br />The safety and efficacy of Ezeact PLUS in children and adolescents aged 0 to &lt;18 years have not<br />been established. No data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use not recommended<br />Lithium<br />Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use<br />of lithium and angiotensin-converting enzyme inhibitors. A similar effect may occur with angiotensin II<br />receptor blockers. Lithium renal clearance is reduced by diuretics, such as chlortalidone, increasing the risk<br />of lithium toxicity.<br />Due to the lack of experience with concomitant use of Ezeact PLUS and lithium, this combination is not<br />recommended. If the combination proves necessary, consider monitoring of serum lithium levels when using<br />Ezeact PLUS.<br />Caution required with concomitant use<br />Non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors, acetylsalicylic acid<br />&gt; 3 g/day), and non-selective NSAIDs<br />When angiotensin II receptor blockers are administered simultaneously with NSAIDs (i.e. selective<br />COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g/day) and non-selective NSAIDs), attenuation of the<br />antihypertensive effect may occur. Furthermore, in patients who are elderly, volume-depleted (including<br />those on diuretic therapy), or who have compromised renal function concomitant use of angiotensin II<br />receptor blockers and NSAIDs may lead to an increased risk of worsening of renal function (including<br />possible acute renal failure) and an increase in serum potassium. Therefore, adequate hydration and<br />monitoring of renal function at the beginning of the treatment are recommended.<br />Potassium supplements, salt substitutes containing potassium and other substances that may increase<br />potassium levels<br />Based on experience with the use of other medicinal products that affect the RAAS, use of Ezeact PLUS<br />with potassium supplements, salt substitutes containing potassium, or other medicinal products that may<br />increase potassium levels (e.g. heparin) may lead to increases in serum potassium in hypertensive patients<br />(see<br />section 4.4).</p><p>Digitalis<br />Coadministration of digitalis may exacerbate the adverse effects of hypokalemia (see section 4.4).<br />Additional information<br />Ezeact PLUS<br />Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through<br />the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher<br />frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including<br />acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<br />The pharmacokinetics of azilsartan medoxomil and chlortalidone is not altered when the drugs are<br />co-administered.<br />No drug interaction studies have been conducted with other drugs and Ezeact PLUS, although studies have<br />been conducted with azilsartan medoxomil and chlortalidone.<br />Azilsartan medoxomil<br />No clinically significant interactions have been reported in studies of azilsartan medoxomil or azilsartan<br />given with amlodipine, antacids, chlortalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin,<br />and warfarin.<br />Azilsartan medoxomil is a prodrug, which is rapidly hydrolysed to the active moiety azilsartan by esterases<br />in the gastrointestinal tract and/or during drug absorption (see section 5.2). In vitro studies indicated that&nbsp;interactions based on esterase inhibition are unlikely.<br />Chlortalidone<br />Diuretics potentiate the action of curare derivatives and antihypertensive agents (e.g. guanethidine,<br />metyldopa, beta-blockers, vasodilators, calcium antagonists, ACE-inhibitors and ARBs).<br />The hypokalaemic effect of chlortalidone may be potentiated by corticosteroids, ACTH, &beta;2-agonists,<br />amphotericin and carbenoloxone.<br />Allopurinol<br />Coadministration of chlortalidone may increase the incidence of hypersensitivity reactions to allopurinol.<br />Amantadine<br />Chlortalidone may increase the risk of adverse effects caused by amantadine.<br />Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of chlortalidone by<br />decreasing gastrointestinal motility and stomach emptying rate.<br />Antidiabetic medicinal products (oral agents and insulin)<br />Dosage adjustment of the antidiabetic medicinal products may be required.<br />Calcium salts<br />The pharmacological effects of both calcium salts and vitamin D may be increased to clinically significant<br />levels if administered together with chlortalidone.<br />Ciclosporin<br />Concomitant treatment with ciclosporin may increase the risk of hyperuricaemia and gout-type<br />complications.</p><p>Colestyramine<br />Absorption of chlortalidone is impaired in the presence of anionic exchange resins. A decrease in the<br />pharmacological effect may be expected.<br />Cytotoxic agents<br />Concurrent administration may reduce renal excretion of cytotoxic medicinal products (e.g.<br />cyclophosphamide, metothrexate) and potentiate their myelosuppressive effects.<br />Diazoxide<br />The hyperglycaemic effect of diazoxide may be enhanced by chlortalidone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Ezeact PLUS should not be used in pregnancy (see section 4.3 and 4.4).<br />The use of angiotensin II receptor blockers is not recommended during the first trimester of pregnancy<br />(see section 4.4).<br />The use of angiotensin II receptor blockers is contraindicated during the second and third trimester of<br />pregnancy (see sections 4.3 and 4.4).<br />Thiazides are contraindicated in pregnancy (see section 4.3 and 4.4).<br />There are no clinical data from the use of Ezeact PLUS in pregnant women. Studies in animals have<br />shown reproductive toxicity (see section 5.3).<br />Azilsartan medoxomil<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to angiotensin converting<br />enzyme inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase<br />in risk cannot be excluded. Whilst there are no controlled epidemiological data on the risk with angiotensin<br />II receptor blockers, similar risks may exist for this class of medicinal products. Unless continued<br />angiotensin II receptor blocker therapy is considered essential, patients planning pregnancy should be<br />changed to alternative anti-hypertensive treatments which have an established safety profile for use in<br />pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor blockers should be stopped<br />immediately and, if appropriate, alternative therapy should be started.<br />Exposure to angiotensin II receptor blocker therapy during the second and third trimesters is known to<br />induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and<br />neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3).<br />Should exposure to angiotensin II receptor blockers have occurred from the second trimester of pregnancy,<br />ultrasound check of renal function and skull is recommended.<br />Infants whose mothers have taken Angiotensin II receptor blockers should be closely observed for<br />hypotension (see sections 4.3 and 4.4).</p><p>Chlortalidone<br />Diuretics should not be used for the management of oedema or hypertension in pregnancy as their use may<br />be associated with hypovolaemia, increased blood viscosity and reduced placental perfusion. Diuretics such<br />as chlortalidone have been shown to cross the placental barrier and appear in cord blood. There have been<br />reports of fetal bone marrow depression, thrombocytopenia, and fetal and neonatal jaundice associated with<br />the use of thiazide-like diuretics.<br />Breastfeeding<br />No information is available regarding the use of Ezeact PLUS or azilsartan medoxomil during breastfeeding.<br />However, chlortalidone passes into breast milk and Ezeact PLUS is therefore not recommended during<br />breastfeeding. Alternative treatments with better established safety profiles during breastfeeding are<br />preferable, especially while nursing a newborn or preterm infant.<br />Fertility<br />No data are available on the effect of Ezeact PLUS on human fertility. Nonclinical studies demonstrated<br />that azilsartan medoxomil did not appear to affect male or female fertility in the rat (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on its pharmacodynamic properties, it is expected that Ezeact PLUS would have negligible<br />influence on the ability to drive and use machines. However, when taking any antihypertensive it should<br />be taken into account that dizziness or tiredness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Ezeact PLUS has been evaluated for safety in clinical studies in patients treated for up to 52 weeks. In<br />these clinical studies, adverse reactions associated with treatment with Ezeact PLUS were mostly mild or<br />moderate. The most common adverse reaction was blood creatinine increased. The increases in blood<br />creatinine were<br />dose-related and mostly transient or nonprogressive while on treatment, and reversible following cessation of<br />treatment. The incidence of adverse reactions with Ezeact PLUS was not affected by gender, age, or race.<br />Clinical Investigation<br />In the short term studies, the safety profile was comparable to active comparators and showed no clinically<br />important differences across diverse subgroups including age, gender, or race. When Ezeact PLUS was<br />administered to patients not adequately controlled on azilsartan medoxomil 40 mg, the overall safety profile<br />of Ezeact PLUS 40 mg/12.5 mg was similar to the safety profile of azilsartan medoxomil 40 mg. Ezeact<br />PLUS 40 mg/25 mg was also safe and well tolerated, although elevated blood creatinine, headache and<br />dizziness occurred more frequently in conjunction with greater blood pressure reduction. In the long term<br />safety study in patients with moderate renal impairment, the adverse events observed were similar for Ezeact<br />PLUS compared with olmesartan medoxomil/hydrochlorothiazide.<br />Cardiovascular outcome studies have shown that long-term treatment with chlortalidone reduces the risk of<br />cardiovascular mortality and morbidity.<br />Tabulated list of adverse reactions<br />Adverse reactions based on pooled data from all Phase 3 clinical trials are listed below according to system<br />organ class and preferred terms. These are ranked by frequency, using the following convention: very<br />common (&ge; 1/10); common (&ge; 1/100, &lt; 1/10); uncommon (&ge; 1/1,000, &lt; 1/100); rare (&ge; 1/10,000, &lt; 1/1,000);<br />very rare (&lt; 1/10,000), including isolated reports. Within each frequency grouping, adverse reactions are<br />presented in order of decreasing seriousness.</p><p>Blood and lymphatic system<br />disorders<br />Uncommon Anaemia</p><p>Metabolism and nutrition<br />disorders<br />Common:Blood uric acid increased, hyperuricaemia<br />Uncommon:Hypokalaemia, blood potassium increased,<br />hyponatraemia, blood sodium decreased, gout</p><p>Nervous system disorders</p><p>Common:Dizziness, dizziness postural<br />Uncommon:Syncope, paraesthesia</p><p>Vascular disorders</p><p>Common Hypotension<br />Gastrointestinal disorders</p><p>Common Diarrhoea, nausea</p><p>Uncommon Vomiting</p><p>&nbsp;</p><p>Skin and subcutaneous tissue<br />disorders<br />Uncommon Rash, pruritus</p><p>Musculoskeletal and<br />connective tissue disorders<br />Common Muscle spasms</p><p>General disorders and<br />administration site conditions<br />Common Fatigue</p><p>Investigations</p><p>Very common:&nbsp;Blood creatinine increased<br />Common:Blood urea increased<br />Uncommon:Blood glucose increased</p><p>Additional information on individual components<br />Adverse reactions known to occur with each component given singly but not seen in the clinical studies may<br />occur during treatment with Ezeact PLUS.<br />Azilsartan medoxomil<br />In addition to the adverse reactions noted above for Ezeact PLUS, the following adverse reactions have<br />been reported for azilsartan medoxomil:<br />Peripheral oedema, migraine, and increased blood creatine phosphokinase were reported as uncommon<br />adverse reactions<br />Renal impairment was reported rarely during the clinical trials. Serious angioedema may occur rarely (&ge;<br />1/10,000 to &lt;1/1,000).<br />Chlortalidone<br />In addition to the adverse reactions noted above for Ezeact PLUS, the following adverse reactions have<br />been reported for chlortalidone:</p><p>Blood and lymphatic system<br />disorders<br />Rare Thrombocytopenia, leucopenia<br />agranulocytosis, eosinophilia<br />Metabolism and nutrition<br />disorders<br />Very common&nbsp;Rise in blood lipids<br />Common&nbsp;Hypomagnesaemia<br />Rare&nbsp;Hypercalcaemia, glycosuria, worsening of<br />diabetic metabolic state<br />Very rare&nbsp;Hypochloraemic alkalosis<br /><br />Nervous system disorders Rare Headache<br />Cardiac disorders Common&nbsp;Postural hypotension<br />Rare Cardiac arrhythmias</p><p>Respiratory, thoracic and<br />mediastinal disorders<br />Rare Idiosyncratic pulmonary oedema</p><p>Gastrointestinal disorders Common&nbsp;Loss of appetite, minor gastrointestinal distress<br />Rare&nbsp;Constipation, gastric pain<br />Very rare&nbsp;Pancreatitis</p><p>Hepatobiliary disorders Rare Intrahepatic cholestasis or jaundice<br />Skin and subcutaneous tissue<br />disorders<br />Common&nbsp;Urticaria<br />Rare&nbsp;Photosensitisation, cutaneous vasculitis<br /><br />Renal and urinary disorders Rare Allergic interstitial nephritis<br />Reproductive system and breast disorders<br />Common Impotence<br />&nbsp;</p><p>Description of selected adverse reactions<br />Renal impairment and renal failure were reported uncommonly in conjunction with blood creatinine<br />increased; the majority was reversible either on treatment or after discontinuation of Ezeact PLUS and<br />none required dialysis.<br />As with other ARBs, serious angioedema may occur rarely (&ge;1/10,000 to &lt;1/1,000).<br />Investigations<br />Serum creatinine<br />Increased blood creatinine is a known pharmacologic effect of RAAS blockers, such as ARBs and ACEinhibitors,<br />and is related to the magnitude of blood pressure reduction. Treatment with Ezeact PLUS<br />resulted in a greater incidence of blood creatinine increases, compared with azilsartan medoxomil and<br />chlortalidone. Elevations were transient or non-progressive and reversible, and associated with large blood<br />pressure reductions.<br />Uric acid<br />Ezeact PLUS was associated with increases in serum uric acid consistent with the known pharmacological<br />effects of diuretics. The uric acid elevations are dose dependent increasing with the chlortalidone dose<br />although reports of gout were infrequent across treatment groups, even in long-term studies.<br />Hemoglobin and hematocrit<br />Ezeact PLUS was associated with small decreases in hematocrit, hemoglobin levels, and red blood cell<br />count, consistent with the known pharmacological effects of inhibitors of the renin-angiotensin-aldosterone<br />system.<br />Post-marketing experience<br />A rare incidence of angioedema has been reported in conjunction with use of Ezeact PLUS. No other<br />adverse reactions have been identified in post-marketing spontaneous reports.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows&nbsp;continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked<br />to report any suspected adverse reactions via national pharmacovigilance and drug safety centre (NPC)<br />To report any side effect(s):<br /> Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available related to overdosage of Ezeact PLUS in humans.<br />Azilsartan medoxomil<br />Based on pharmacological effects, the main manifestation of an overdose of azilsartan medoxomil is likely to<br />be symptomatic hypotension and dizziness. During controlled clinical studies in healthy subjects, once daily<br />doses up to 320 mg of Ezeact were administered for 7 days and were well tolerated.<br />If symptomatic hypotension should occur, supportive treatment should be instituted and vital signs<br />monitored. Azilsartan is not removed by dialysis.<br />Chlortalidone<br />Symptoms of chlortalidone overdose include nausea, weakness, dizziness, and disturbances of electrolyte<br />balance. There is no specific antidote, but gastric lavage is recommended, followed by supportive treatment.<br />Blood pressure and fluid and electrolyte balance should be monitored and appropriate corrective measures<br />taken. Intravenous fluid and electrolyte replacement may be indicated.<br />&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics, ATC code: C09DA09.<br />Ezeact PLUS is a combination of two antihypertensive agents with complementary mechanisms to control<br />blood pressure: the prodrug of an angiotensin II AT1 receptor antagonist, azilsartan medoxomil, and a<br />thiazide-like diuretic, chlortalidone.<br />Mechanism of action and pharmacodynamic effect<br />Azilsartan medoxomil is an orally administered prodrug that is rapidly converted by esterases in the<br />gastrointestinal tract and/or during absorption to the active moiety, azilsartan, which selectively antagonises<br />the effects of angiotensin II by blocking its binding to the AT1 receptor in multiple tissues (see section 5.2).<br />Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include<br />vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal<br />reabsorption of sodium.<br />Blockade of the AT1 receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion,<br />but the resulting increases in plasma renin activity and angiotensin II circulating levels do not overcome the<br />antihypertensive effect of azilsartan.<br />Chlortalidone produces diuresis with increased excretion of sodium and chloride. The site of action appears<br />to be the early convoluted part of the distal renal tubule in the nephron. The diuretic effect of chlortalidone is<br />due to inhibition of sodium reabsorption inhibiting Na+Cl- reabsorption by antagonising the Na+Clcotransporter<br />at that site which leads to increased sodium and water excretion<br />Clinical efficacy and safety<br />Clinical efficacy<br />Nearly additive reduction of blood pressure provided by the individual components was observed across the<br />therapeutic dose range that persists for 24 hours.</p><p>In an 8-week, multicenter, randomized, double-blind, active-controlled, parallel group factorial study,<br />1714 patients with moderate to severe essential hypertension were randomized to one of the 11 active<br />treatment arms that compared the relative effect on blood pressure of Ezeact PLUS with the respective<br />monotherapy components without titration. Ezeact PLUS treatment combinations resulted in significantly<br />greater reduction in systolic and diastolic blood pressure compared with the respective individual<br />monotherapies as determined by clinic blood pressure measurements (see Table 1). Ambulatory blood<br />pressure monitoring (ABPM) of trough blood pressure (22-24 hours post-dose) had similar results.<br />&nbsp;</p><p>In a multicenter, randomized, double-blind, active-controlled, parallel group study of patients with grade 2 or<br />3 hypertension, not controlled adequately on azilsartan medoxomil 40 mg, target clinic systolic blood<br />pressure (&lt;140 mm Hg for the general population and &lt;130 mm Hg for those with diabetes or CKD) was<br />achieved in 63% of patients treated with azilsartan medoxomil and chlortalidone 40 mg/12.5 mg and 78% of<br />patients treated with azilsartan medoxomil and chlortalidone 40 mg/25 mg, compared to 35% of patients<br />remaining on azilsartan medoxomil 40 mg. Following an initial 4-week treatment with Ezeact 40 mg,<br />treatment with Ezeact PLUS of those subjects whose blood pressure remained equal to or higher than 140<br />mm Hg resulted in a reduction in systolic/diastolic blood pressure of 15.8/7.7 mm Hg (40 mg/12.5 mg) and<br />21.1/10.3 mm Hg (40 mg/25 mg) compared to patients who remained on azilsartan medoxomil 40 mg of<br />6.4/3.2 mm Hg.<br />In two randomized, double-blind titration studies, azilsartan medoxomil and chlortalidone produced greater<br />reduction in systolic and diastolic blood pressure compared to olmesartan medoxomil/hydrochlorothiazide<br />in patients with moderate to severe hypertension.<br />Ezeact PLUS&rsquo;s blood pressure lowering effects are maintained throughout the 24-hour period, with most<br />of the antihypertensive effect of Ezeact PLUS occurring within 1-2 weeks of dosing and being maintained<br />for up to 12 months of evaluation.<br />Ezeact PLUS led to robust reductions in all blood pressure parameters across diverse subgroups including<br />age, gender, or race. In black patients in particular, treatment with Ezeact PLUS resulted in blood pressure<br />reductions that were generally similar to the overall population, despite a known attenuated response to<br />RAAS blockade in this population.<br />Effect on cardiac repolarisation<br />A thorough QT/QTc study was conducted to assess the potential of azilsartan medoxomil to prolong the<br />QT/QTc interval in healthy subjects. There was no evidence of QT/QTc prolongation at a dose of 320<br />mg azilsartan medoxomil.</p><p>Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies with Ezeact<br />PLUS (azilsartan medoxomil/chlortalidone) in all subsets of the paediatric population in hypertension as<br />per Paediatric Investigation Plan (PIP) decision (EMA/PDCO/430493/2012), in the granted indication<br />(see section 4.2 for information on paediatric use).<br />Additional information<br />Two large randomised, controlled trials ONTARGET (ONgoing Telmisartan Alone and in combination with<br />Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)<br />have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.<br />ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease,<br />or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in<br />patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and<br />mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to&nbsp;monotherapy was observed. Given their similar pharmacodynamic properties, these results are also<br />relevant for other ACE-inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients<br />with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 diabetes Using Cardiovascular and Renal Disease Endpoints) was a<br />study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an<br />angiotensin receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease,<br />cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse<br />outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than<br />in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension<br />and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p><p><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant administration of azilsartan 80 mg and chlortalidone 25 mg once daily for 7 days does not<br />affect the PK of either substance in healthy subjects.<br />Following oral administration of the fixed dose tablet, the peak plasma concentration (Cmax) of chlortalidone<br />is 45% higher compared to administration of chlortalidone and azilsartan as separate tablets. The extent of<br />absorption as defined by the area under the curve (AUC) of both azilsartan and chlortalidone following<br />administration of Ezeact PLUS is similar to that when azilsartan and chlortalidone are administered as<br />separate tablets.<br />Ezeact PLUS may be administered with or without food.<br />The following section outlines the pharmacokinetic properties of the individual components of Ezeact PLUS<br />(azilsartan medoxomil/chlortalidone) as reported in their respective Summary of Product Characteristics.<br />Absorption<br />Azilsartan medoxomil<br />Following oral administration, azilsartan medoxomil is rapidly hydrolyzed to azilsartan, the active<br />metabolite, in the gastrointestinal tract during absorption. Azilsartan medoxomil is not detected in plasma<br />after oral administration. Based on in vitro studies, carboxymethylenebutenolidase is involved in the<br />hydrolysis in the intestine and liver. In addition, plasma esterases are involved in the hydrolysis of azilsartan<br />medoxomil to azilsartan.<br />The estimated absolute oral bioavailability of azilsartan medoxomil based on plasma levels of azilsartan is<br />approximately 60%. After oral administration of azilsartan medoxomil, the time to maximal concentration<br />(Tmax) of azilsartan is reached within 1.5 to 3 hours. Food does not affect the bioavailability of azilsartan (see<br />section 4.2).<br />Chlortalidone<br />The estimated bioavailability of chlortalidone is approximately 64%, after 8 to 12 hours post dose. On<br />repeated daily doses of 50 mg, mean steady state blood concentration of 7.2 &mu;g/ml (21.2 &mu;mo/L), measured<br />at the end of the 24 hour dosage interval, is reached after 1 to 2 weeks.<br />Distribution</p><p>Azilsartan medoxomil<br />The volume of distribution of azilsartan is approximately 16 litres. Azilsartan is highly bound to plasma<br />proteins (&gt;99%), mainly serum albumin. Protein binding is constant at azilsartan plasma concentrations well<br />above the range achieved with recommended doses.<br />Chlortalidone<br />In whole blood, chlortalidone is predominantly bound to erythrocyte carbonic anhydrase. In vitro, plasma<br />protein binding of chlortalidone is approximately 76%, with the major binding protein being albumin.<br />Chlortalidone crosses the placental barrier and passes into the breast milk. In mothers treated with 50 mg<br />chlortalidone daily before and after delivery, chlortalidone levels in fetal whole blood were about 15% of<br />those found in maternal blood. Chlortalidone concentrations in amniotic fluid and in the maternal milk are<br />approximately 4% of the corresponding maternal blood level.<br />Biotransformation<br />Azilsartan medoxomil<br />Azilsartan is metabolised to two primary metabolites. The major metabolite in plasma is formed by Odealkylation,<br />referred to as metabolite M-II, and the minor metabolite is formed by decarboxylation, referred<br />to as metabolite M-I. Systemic exposures to the major and minor metabolites in humans were approximately<br />50% and less than 1% that of azilsartan, respectively. M-I and M-II do not contribute to the pharmacologic<br />activity of Ezeact PLUS. The major enzyme responsible for azilsartan metabolism is CYP2C9.</p><p>Chlortalidone<br />Metabolism and hepatic excretion into bile constitute a minor pathway of elimination. Within 120 hours,<br />about 70% of the dose is excreted in the urine and the faeces, mainly in unchanged form.<br />Elimination<br />Azilsartan medoxomil<br />Following an oral dose of 14C-labelled azilsartan medoxomil, approximately 55% of radioactivity was<br />recovered in faeces and approximately 42% in urine, with 15% of the dose excreted in urine as azilsartan.<br />The elimination half-life of azilsartan is approximately 11 hours and renal clearance is approximately<br />2.3 ml/min. Steady-state levels of azilsartan are achieved within 5 days and no accumulation in plasma<br />occurs with repeated once-daily dosing.<br />Chlortalidone<br />Chlortalidone is eliminated from whole blood and plasma with an elimination half-life averaging 50 hours.<br />The elimination half-life is unaltered after chronic administration. The major part of an absorbed dose of<br />chlortalidone is excreted by the kidneys, with a mean renal clearance of 60 ml/min.<br />Linearity/non-linearity<br />Azilsartan medoxomil<br />Dose proportionality in exposure was established for azilsartan in the azilsartan medoxomil dose range of<br />20 mg to 320 mg after single or multiple dosing.<br />Chlortalidone<br />For doses of 25 mg and 50 mg, Cmax values average 1.5 &mu;g/ml (4.4 &mu;mol/L) and 3.2 &mu;g/ml (9.4 &mu;mol/L)<br />respectively. For doses up to 100 mg there is a proportional increase in AUC.<br />Special populations<br />Paediatric population<br />The pharmacokinetics of azilsartan has been studied in paediatric subjects with hypertension, between the<br />ages of 4 to 16 years. However, safety and efficacy in paediatric patients has not been established.<br />The pharmacokinetics of chlortalidone is not available in children under 18 years of age.</p><p>Older population<br />Pharmacokinetics of azilsartan does not differ significantly between young (age range 18-45 years) and<br />elderly (age range 65-85 years) patients.<br />In elderly patients, the elimination of chlortalidone is slower than in healthy young adults, although<br />absorption is the same. Therefore, caution is recommended when treating the very elderly (&ge;75 years) with<br />Ezeact PLUS (see section 4.2).<br />Renal impairment<br />In patients with mild, moderate, and severe renal impairment azilsartan total exposure (AUC) was +30%,<br />+25% and +95% increased. No increase (+5%) was observed in end-stage renal disease patients who were<br />dialysed. However, there is no clinical experience in patients with severe renal impairment<br />(GFR &lt;30 mL/min/1.73m2) or end stage renal disease (see section 4.2). Haemodialysis does not remove<br />azilsartan from the systemic circulation.<br />The major part of an absorbed dose of chlortalidone is excreted by the kidneys; however renal dysfunction<br />does not alter the pharmacokinetics of chlortalidone. The rate-limiting factor in the elimination of<br />chlortalidone from blood or plasma is most probably the affinity of the drug to the carbonic anhydrase of<br />erythrocytes. As a result, no dosage adjustment is needed for Ezeact PLUS in patients with mild and<br />moderately impaired renal function (GFR &ge;30-&lt; 90 mL/min/1.73 m2).</p><p>Hepatic impairment<br />Administration of azilsartan medoxomil for up to 5 days in subjects with mild (Child-Pugh A) or moderate<br />(Child-Pugh B) hepatic impairment resulted in a slight increase in azilsartan exposure (AUC increased by<br />1.3 to 1.6 fold). Azilsartan has not been studied in patients with severe hepatic impairment. Chlortalidone has<br />not been studied in patients with hepatic impairment.<br />Ezeact PLUS is contraindicated in patients with severely impaired hepatic function (see section<br />4.2). Gender<br />Pharmacokinetics of azilsartan does not differ significantly between males and females. In a population<br />pharmacokinetic analysis of patients with hypertension receiving Ezeact PLUS, male subjects had a<br />lower exposure (Cmax and AUC) than female subjects (&le;30%). The differences in pharmacokinetics are<br />not considered clinically relevant.<br />No dose adjustment is necessary based on gender.<br />Race<br />Pharmacokinetics of azilsartan does not differ significantly between black and white populations. In a<br />population pharmacokinetic analysis of patients with hypertension receiving Ezeact PLUS, there was no<br />effect of race on the pharmacokinetics of azilsartan or chlortalidone.<br />No dose adjustment is necessary based on race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azilsartan medoxomil/chlortalidone<br />No mutagenicity, carcinogenicity or fertility studies have been conducted with the combination of azilsartan<br />medoxomil and chlortalidone.<br />The decreased plasma potassium levels and renal corticomedullary mineralization attributed to chlortalidone<br />treatment were not observed after treatment with chlortalidone, azilsartan medoxomil and M-II in<br />combination. There were no unexpected or unique toxicities associated with dosing of the combination.<br />In an embryo-fetal developmental study in rats, there was no teratogenicity or increase in fetal mortality in<br />the litters of dams receiving azilsartan medoxomil, M-II and chlortalidone concomitantly during the period<br />of organogenesis at maternally toxic doses.<br />Azilsartan medoxomil<br />In preclinical safety studies, azilsartan medoxomil and M-II, the major human metabolite, were examined for<br />repeated-dose toxicity, reproduction toxicity, mutagenicity and carcinogenicity. In the repeated-dose toxicity<br />studies, doses producing exposure comparable to that in the clinical therapeutic range caused reduced red<br />cell parameters, changes in the kidney and renal haemodynamics, as well as increased serum potassium in<br />normotensive animals. These effects, which were prevented by oral saline supplementation, do not have<br />clinical significance in treatment of hypertension.<br />In rats and dogs, increased plasma renin activity and hypertrophy/hyperplasia of the renal juxtaglomerular<br />cells were observed. These changes, also a class effect of angiotensin converting enzyme inhibitors and other<br />angiotensin II receptor blockers, do not appear to have clinical significance.</p><p>Azilsartan and M-II crossed the placenta and were found in the fetuses of pregnant rats and were excreted<br />into the milk of lactating rats. In the reproductive and developmental toxicity studies, there were no effects<br />on male or female fertility and no evidence of a teratogenic effect in rats or rabbits. However, in peri- and<br />post-natal animal studies, in which dosing of pregnant animals was continued through lactation, some<br />hazardous potential to the postnatal development of the offspring was seen, such as lower body weight, a<br />slight delay in physical development (delayed incisor eruption, pinna detachment, eye opening), and higher<br />rates of mortality. Azilsartan and M-II showed no evidence of mutagenicity or relevant clastogenic activity<br />in in vitro or in vivo studies and no evidence of carcinogenicity in rats or mice.<br />Chlortalidone<br />Reports in the literature indicate that treatment with chlortalidone does not produce reproductive toxicity in<br />dams or cause embryo-fetal mortality or teratogenicity in pregnant mice, rats, hamsters or rabbits.<br />Chlortalidone has been demonstrated to be a safe and effective prophylactic treatment for toxemia in gravid<br />women at least 30 weeks pregnant and at high risk for developing the condition.<br />Environmental Risk Assessment<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol (E 421)<br />Fumaric acid (E 297) (for pH adjustment)<br />Sodium hydroxide (for pH adjustment)<br />Hydroxypropylcellulose (E 463)<br />Crospovidone (Type A)<br />Cellulose, microcrystalline (E 460)<br />Magnesium stearate (E 572)<br />Titanium dioxide (E171)<br />Iron oxide, red (E172)<br />Hypromellose 2910<br />Talc<br />Macrogol 8000<br />Printing ink grey F1:<br />Shellac<br />Iron oxide, black (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture.<br />Do not store above 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cartons containing desiccated or non-desiccated aluminum/aluminum blister packs (contains PE and PVC).<br />Pack sizes:<br />One blister pack contains 14 tablets.<br />14, 28 or 56 tablets.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Batterjee pharmaceutical factory
Industrial Area-phase-IV,
Jeddah-21443, Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>